Application note: Developing next-gen in vitro Huntington’s disease assays
The use of high-density MEAs to probe single cell and network activity electrophysiology of a hiPSC-derived Huntington’s disease model
List view / Grid view
Biomarkers are a naturally occurring molecule, gene, or characteristic by which a particular disease can be identified.
The use of high-density MEAs to probe single cell and network activity electrophysiology of a hiPSC-derived Huntington’s disease model
Explore pathways of cell cycle control, revealing mechanisms of cell cycle arrest, DNA damage and senescence using this ebook.
US researchers discover a potential therapeutic avenue through the molecule NgR2, against an aggressive form of prostate cancer.
Advance your neurodegeneration research with our broad antibody portfolio, ready-to-use ELISA, and cellular kits to develop new efficacious therapies.
What is multiplexed immunofluorescence microscopy imaging?
Development of novel rabbit monoclonal antibodies to characterise microglial activation states in murine models of Alzheimer’s disease.
Need some direction in choosing immune cell markers? Whether you are working with human cells or a mouse model, CST has you covered!
Simultaneous multicolour imaging for successful experiments.
Dr Sheraz Gul examines how patient-driven imaging strategies can be utilised to aid the translation of initial research all the way into the clinic.
Read about the current state of the industry, challenges associated with potency assays and measuring product potency throughout the manufacturing process.
Understand how quality control assays are being implemented in monitoring the development of CAR-T cells using high-throughput technologies in this article.
Cytokine multiplex assays allow researchers to measure multiple cytokines, chemokines and growth factors from one small sample.
Measure protein, DNA and RNA in FFPE tissue samples using rigorously IHC validated CST antibodies on the NanoString® nCounter® platform.
Researchers have identified a protein that, when present in high amounts in breast cancer tumours, is an indicator of whether DNA-damaging therapies will work or not.
Dr. Stokes, Associate Director Proteomics, discusses how proteomic studies can increase effectiveness, speed of target and biomarker identification.